Trial
NCT01044745
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Nebraska
Collaborators
National Cancer Institute (NCI)
Condition
Accelerated Phase Chronic Myelogenous Leukemia
Intervention
rituximab
Why stopped
Study was closed to accrual for safety related to the frequency of BK infections.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-09-06